Somatic mutations are present in all members of the AKT family in endometrial carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. AKT mutant allele-specific activation dictates pharmacologic sensitivities.Nature communications · 2022
   Trial
2. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.Gynecologic oncology · 2016
   Trial
3. Endometrial cancer: from clinical reality to molecular treatment.Discover oncology · 2025
   Review
4. Akt: A Potential Drug Target for Metabolic Syndrome.Frontiers in physiology · 2022
   Review
5. Targeting Akt in cancer for precision therapy.Journal of hematology & oncology · 2021
   Review
6. Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma.ACS pharmacology & translational science · 2020
   Article
7. Cancer-Related Triplets of mRNA-lncRNA-miRNA Revealed by Integrative Network in Uterine Corpus Endometrial Carcinoma.BioMed research international · 2017
   Article
8. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016
   Article
9. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.Gynecologic oncology · 2016
   Review
10. Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity.Oncotarget · 2016
    Article
11. PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.Journal of cellular physiology · 2012
    Review
12. The genomics and genetics of endometrial cancer.Advances in genomics and genetics · 2012
    Article
13. Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.Journal of oncology · 2012
    Article
14. Personalized therapy in endometrial cancer: challenges and opportunities.Cancer biology & therapy · 2012
    Review
15. Human Papillomaviruses, p16INK4a and Akt expression in basal cell carcinoma.Journal of experimental & clinical cancer research : CR · 2011
    Article
16. Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.Endocrine pathology · 2011
    Article
17. Molecular profiling of endometrial malignancies.Obstetrics and gynecology international · 2010
    Article
18. Genetics of endometrial cancers.Obstetrics and gynecology international · 2010
    Article

Corrections and comments

• Comment on
  The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.2009

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as